GoAI
Get started
IGC Pharma, Inc. logo

IGC Pharma, Inc.

IGC

AMEXHealthcareBiotechnology

Open in GoAI

Regular session

$0.306

−$0.002 · -0.65%

Aug 24, 10:08 AM ET

IGC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

22

Expensive

Momentum

29

Weakening

Sentiment

53

Mixed

Risk resilience

50

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Ram Mukunda
Listed since
May 24, 2006
Employees
70

Market position

Day range

Current $0.306

52-week range

Current $0.306

Open
$0.3001
Previous close
$0.308
Volume
559.63K
0.52× average
Average volume
1.09M
Average daily volume
Market cap
30.63M USD
Beta
0.46
Market reference 1
50-day average
$0.2708
+13.00% above average
200-day average
$0.2925
+4.62% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
25.71M USD
P/E (TTM)
-3.72×
P/B (TTM)
5.01×
P/S (TTM)
27.27×
EV / EBITDA
-4.13×
Earnings yield
-26.20%
Free cash flow yield
-24.43%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
21.91%
Operating margin
-986.82%
Net margin
-702.14%
Return on equity
-106.98%
Return on assets
-71.29%
Return on invested capital
-144.79%

Financial health

Debt / equity
0.18×
Current ratio
0.4×
Altman Z-score
-16.52
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends449%-1128%-2704%-4280%Gross margin, FY2022: 48.87%Gross margin, FY2023: -17.34%Gross margin, FY2024: 54.50%Gross margin, FY2025: 48.70%Gross margin, FY2026: 29.68%Operating margin, FY2022: -3886.15%Operating margin, FY2023: -1270.14%Operating margin, FY2024: -728.48%Operating margin, FY2025: -585.84%Operating margin, FY2026: -860.29%Net margin, FY2022: -3782.37%Net margin, FY2023: -1263.01%Net margin, FY2024: -966.54%Net margin, FY2025: -560.27%Net margin, FY2026: -552.11%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 48.87%. Gross margin FY2023 -17.34%. Gross margin FY2024 54.50%. Gross margin FY2025 48.70%. Gross margin FY2026 29.68%. Operating margin FY2022 -3886.15%. Operating margin FY2023 -1270.14%. Operating margin FY2024 -728.48%. Operating margin FY2025 -585.84%. Operating margin FY2026 -860.29%. Net margin FY2022 -3782.37%. Net margin FY2023 -1263.01%. Net margin FY2024 -966.54%. Net margin FY2025 -560.27%. Net margin FY2026 -552.11%.

Income trends

Revenue

1.19M USD-6.69%

Operating income

−10.2M USD-37.03%

Net income

−6.55M USD+8.05%
Income trends across reported periods3.02M USD−3.69M USD−10.4M USD−17.11M USDRevenue, FY2022: 397K USDRevenue, FY2023: 911K USDRevenue, FY2024: 1.35M USDRevenue, FY2025: 1.27M USDRevenue, FY2026: 1.19M USDOperating income, FY2022: −15.43M USDOperating income, FY2023: −11.57M USDOperating income, FY2024: −9.8M USDOperating income, FY2025: −7.45M USDOperating income, FY2026: −10.2M USDNet income, FY2022: −15.02M USDNet income, FY2023: −11.51M USDNet income, FY2024: −13M USDNet income, FY2025: −7.12M USDNet income, FY2026: −6.55M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 397K USD. Revenue FY2023 911K USD. Revenue FY2024 1.35M USD. Revenue FY2025 1.27M USD. Revenue FY2026 1.19M USD. Operating income FY2022 −15.43M USD. Operating income FY2023 −11.57M USD. Operating income FY2024 −9.8M USD. Operating income FY2025 −7.45M USD. Operating income FY2026 −10.2M USD. Net income FY2022 −15.02M USD. Net income FY2023 −11.51M USD. Net income FY2024 −13M USD. Net income FY2025 −7.12M USD. Net income FY2026 −6.55M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue1.19M USD1.27M USD1.35M USD911K USD397K USD
Cost of goods sold834K USD652K USD612K USD1.07M USD203K USD
Gross profit352K USD619K USD733K USD−158K USD194K USD
Research and development5.19M USD3.66M USD3.77M USD3.46M USD2.33M USD
Selling, general, and administrative5.36M USD4.41M USD6.76M USD7.95M USD13.29M USD
Operating expenses10.56M USD8.07M USD10.53M USD11.41M USD15.62M USD
Depreciation and amortization324K USD464K USD637K USD657K USD651K USD
Operating income−10.2M USD−7.45M USD−9.8M USD−11.57M USD−15.43M USD
Net income−6.55M USD−7.12M USD−13M USD−11.51M USD−15.02M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
30%
3 beats, 3 misses, 4 met estimates
Average EPS surprise
-87.93%
10 comparable reports
Latest EPS result
-0.03
Estimate -0.02 · Miss by 50.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.02-0.03-0.05-0.07Q2 '25MetQ3 '25BeatQ4 '25MetQ1 '26MetQ2 '26MetQ3 '26MissQ4 '26EstimateQ1 '27Estimate
Q2 2025, reported Jun 30, 2025: actual -0.02, estimate -0.02, surprise 0.00%, Met estimate. Q3 2025, reported Aug 19, 2025: actual -0.02, estimate -0.025, surprise +20.00%, Beat. Q4 2025, reported Nov 14, 2025: actual -0.02, estimate -0.02, surprise 0.00%, Met estimate. Q1 2026, reported Mar 20, 2026: actual -0.02, estimate -0.02, surprise 0.00%, Met estimate. Q2 2026, reported May 15, 2026: actual -0.02, estimate -0.02, surprise 0.00%, Met estimate. Q3 2026, reported Aug 14, 2026: actual -0.03, estimate -0.02, surprise -50.00%, Miss. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.02, surprise —, Comparison unavailable. Q1 2027, reported Feb 5, 2027: actual —, estimate -0.02, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates405.96K297.84K189.72K81.6KQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26EstimateQ1 '27Estimate
Q2 2025, reported Jun 30, 2025: actual 260K USD, estimate 305K USD, surprise -14.75%, Miss. Q3 2025, reported Aug 19, 2025: actual 328K USD, estimate 326K USD, surprise +0.61%, Beat. Q4 2025, reported Nov 14, 2025: actual 191K USD, estimate 383K USD, surprise -50.13%, Miss. Q1 2026, reported Mar 20, 2026: actual 246.5K USD, estimate 250K USD, surprise -1.40%, Miss. Q2 2026, reported May 15, 2026: actual 317K USD, estimate 198K USD, surprise +60.10%, Beat. Q3 2026, reported Aug 14, 2026: actual 265K USD, estimate 164K USD, surprise +61.59%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate 164K USD, surprise —, Comparison unavailable. Q1 2027, reported Feb 5, 2027: actual —, estimate 96K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions
Alliance Global PartnersmaintainBuy

IGC news

accessnewswire.com

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage…

Read source
accessnewswire.com

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that…

Read source
accessnewswire.com

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, today announced that…

Read source
accessnewswire.com

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development POTOMAC, MD / ACCESS…

Read source
accessnewswire.com

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS Newswire / July 7,…

Read source
accessnewswire.com

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London POTOMAC, MD / ACCESS…

Read source

Corporate actions

Corporate action history

Stock split

Effective Apr 19, 2013

1:10

IGC peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$234.72

+0.56%

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.165

-4.09%

Electromed, Inc. logo

ELMD

Electromed, Inc.

$40.59

+2.89%

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.065

-1.39%

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.0001

-1.72%

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.355

-1.05%

ETFs holding IGC

Funds reporting this stock among their holdings, ordered by reported position size.

AdvisorShares Psychedelics ETF logoAdvisorShares Psychedelics ETFPSIL
Market value
250.2K
Weight
0.43%
AUM
57.72M USD
Expense ratio
1.84%
Price / 1D
$25.2171-2.49%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
202.91K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.7-0.75%

Continue in GoAI

Research IGC

research.disclaimer